MaxCyte, Inc. (MXCT)

MaxCyte, Inc. (MXCT) is a healthcare company (medical devices) based in the United States. The share price is $1.23, up 4.24% on the day, which values the company at $127M. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$1.23+4.24% today
Market value
$127M
Funk Score
33/100
Against its own history
Well below its usual priceusual price $3.53
200-week average
$3.0460% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

MaxCyte, Inc. in more detail

MXCT trades at -5.3× next year's expected earnings, 4.1× sales. Measured against its own history, the price is 65% below what its usual multiples would imply ($3.53) — well below its usual price. It sits 60% below its 200-week average of $3.04.

Over the last five fiscal years MaxCyte, Inc. has compounded revenue 16.4% a year. Its Funk Score is 33 out of 100 (financial strength 4.1, profitability 0.0, growth 4.1, value 5.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold MXCT, including Eric Bannasch (0.2% of the portfolio).

Superinvestors holding MXCT

1 of the investors tracked here report a position in their latest 13F filing.

MaxCyte, Inc. (MXCT): questions and answers

What is MaxCyte, Inc.'s market cap?

MaxCyte, Inc. is valued at $127M at a share price of $1.23.

Is MXCT overvalued or undervalued?

Against its own history, MXCT is well below its usual price: the price is 65% below the $3.53 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is MXCT above its 200-week moving average?

No. MXCT is 59.6% below its 200-week average of $3.04. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is MaxCyte, Inc. growing?

Over the last five fiscal years MaxCyte, Inc.'s revenue grew 16.4% a year.

Does MXCT pay a dividend?

MaxCyte, Inc. does not currently pay a regular dividend.

Which famous investors own MXCT?

In their latest quarterly filings, Eric Bannasch (0.2% of the portfolio) hold MXCT. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “MaxCyte, Inc. (MXCT) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/MXCT

Underlying data: Yahoo Finance; company filings with the SEC.